Geneva, March 23 -- International Clinical Trials Registry received information related to the study (NCT07459998) titled 'SKB103 for Injection in Advanced Solid Tumors' on March 4.

Study Type: Interventional

Study Design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Condition: Advanced Solid Tumors

Intervention: Drug: SKB103 for injection monotherapy

Recruitment Status: Not recruiting

Phase: Phase 1/Phase 2

Date of First Enrollment: April 30, 2026

Target Sample Size: 277

Countries of Recruitment: China

To know more, visit https://clinicaltrials.gov/study/NCT07459998

Disclaimer: Cur...